F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified haloindole macrocyclic compounds acting as GTPase KRAS (G12C mutant) inhibitors and thus reported to be useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented new NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, Parkinson’s and Alzheimer’s diseases.
Novel non-addicting analgetic therapies are urgently needed to reduce the use of opiates as painkillers. With the recent discovery that nicotinic acetylcholine receptors (nAChRs) in the immune system can be stimulated to decrease the release of pro-inflammatory cytokines, the cholinergic anti-inflammatory systems (CAS) have generated significant interest in treating pain associated with inflammation.
Jiangxi Jemincare Group Co. Ltd. has reported that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co. Ltd., recently received approvals for clinical trials of five of its drugs in the fields of cancer, kidney and infectious diseases.
Retinoic acid receptor-γ (RARγ) agonism is a key factor in CD8 T-cell-mediated immunity to infectious pathogens. The lack of studies on the effects of RARγ agonists on in vivo tumor growth of triple-negative (TNBC) or HER2+ breast cancers make it necessary to investigate whether RARγ could play a critical role in T-cell-mediated immunity in these breast cancers, using novel RARγ nuclear agonists.
HST-1021 is a novel mucosa-associated lymphoid tissue lymphoma translocation protein (MALT1) allosteric inhibitor identified using the Smart Allostery Platform, and is being developed for the potential treatment of tumors.
Elpiscience Biopharma Ltd. and Astellas Pharma Inc. have announced a research collaboration and license agreement for two novel bispecific macrophage engagers – ES-019 and another program.
Nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) plays a central role in cancer metabolism as well as in metabolism in healthy tissues. Remedy Plan Therapeutics Inc. has presented data on the first hyperbolic Nampt inhibitor – RPT-1G – for the potential treatment of acute myeloid leukemia (AML).
RSS
